The global myopia and presbyopia treatment market was valued at USD 22.5 billion in 2025. The market is projected to grow from USD 24.35 billion in 2026 to USD 46.35 billion by 2034, exhibiting a compound annual growth rate of 8.38% during the forecast period. Contrive Datum Insights presents this information in its report titled "Myopia And Presbyopia Treatment Market Size, Share & Industry Analysis, By Type (Eyeglasses, Contact Lenses, Intra Ocular Lenses, Other), Indication (Myopia, Presbyopia, Combined (Dual Condition)), End user (Hospitals & Specialty Eye Clinics, Optical Retail Chains, Online / E-commerce, Others), Age group (Pediatric (Below 18 Years), Adults (18-40 Years), Presbyopic Adults (41-60 Years), Geriatric (Above 60 Years)), Payer type (Out-of-Pocket Payment, Private Insurance, Public & Government Programs), and Regional Forecast, 2026-2034".
Myopia and presbyopia treatment products correct or manage the two most common refractive vision disorders: nearsightedness that typically develops in childhood and the age-related loss of near focus that affects nearly every adult past midlife. The category spans everyday corrective eyewear and contact lenses through implantable and surgical options used during cataract and refractive procedures, along with emerging pharmacological and orthokeratology approaches aimed at slowing myopia progression in children. Buyers range from individual patients purchasing through optical retailers and online channels to hospitals and ophthalmic surgery centers procuring implantable lenses and diagnostic equipment.
Rising global myopia prevalence, led by pediatric onset in Asia Pacific
Rising global myopia prevalence, led by pediatric onset in Asia Pacific is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 8.38% a year, the type lines exposed to it move fastest: Other compounds at 10.72%, taking its share of revenue from 14% to 17% and its value from USD 3.15 billion to USD 7.88 billion.
On the upside, the study's bull case assumes the bull case assumes faster adoption of premium presbyopia-correcting IOLs and quicker rollout of publicly funded myopia-control programs across Asia Pacific school systems, which would take 2034 revenue to USD 50.2 billion rather than the USD 46.35 billion base case.
However, the bear case assumes slower premium-lens adoption as out-of-pocket cost sensitivity persists and public reimbursement for elective vision correction expands more slowly than expected, which would hold 2034 revenue to USD 42.5 billion. Eyeglasses, which carries 34% of 2025 revenue, already grows at only 6.04% against the market's 8.38%, so the largest part of the base is also its slowest.
Key Players Compete on Eyeglasses Volume and Other Growth
Competition in the global myopia and presbyopia treatment market runs along the type axis rather than the regional one. Eyeglasses holds 34% of 2025 revenue at USD 7.65 billion and remains the largest line through 2034 at 28%, making it the position hardest for a challenger to take. Other, growing at 10.72%, is where share actually changes hands. A supplier established in one is not thereby established in the other, which is what sustains a field of this size in a market of USD 22.5 billion.
Further Report Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Type | Eyeglasses | 34% · USD 7.65 billion | — |
| Indication | Myopia | 46% · USD 10.35 billion | Combined (Dual Condition) 9.21% |
| End user | Hospitals & Specialty Eye Clinics | 42% · USD 9.45 billion | Online / E-commerce 12.26% |
| Age group | Presbyopic Adults (41-60 Years) | 34.98% · USD 7.87 billion | Geriatric (Above 60 Years) 10.57% |
| Payer type | Out-of-Pocket Payment | 48% · USD 10.8 billion | Public & Government Programs 10.24% |
- Based on regional analysis, Asia Pacific led the global myopia and presbyopia treatment market in 2025 with 36% of global revenue at USD 8.1 billion, reaching USD 18.54 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 36% in 2025 to 40% in 2034, with revenue growing from USD 8.1 billion to USD 18.54 billion.
- Middle East and Africa remains the smallest region throughout, at 6% of 2025 revenue and 6% by 2034.
- Other is projected to grow at 10.72% over the forecast period, the fastest of any type line.
- The United States is the largest single country market at USD 5.36 billion in 2025, 23.82% of global revenue.
The report segments the market across five axes; by type, and by indication, end user, age group and payer type; with revenue and a growth rate for every line in every year from 2020 to 2034, alongside bear, base and bull scenarios for the headline total at USD 42.5 billion and USD 50.2 billion by 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. Delivered as a PDF; a free sample is available on request.